The Alliance for Clinical Trials in Oncology today announced that an independent Data and Safety Monitoring Board (DSMB) determined that the phase III CABINET (A021602) pivotal trial met its primary endpoint at an interim ...
Aug 24, 2023
0
73
Patients with advanced kidney cancer are routinely given immune checkpoint inhibitors (ICIs) as first-line treatment. The CONTACT-03, phase 3 clinical trial tested the effects of giving ICIs again, as part of a standard second-line ...
Jun 5, 2023
0
36
A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by an oncologist from Dana-Farber Cancer ...
May 10, 2023
0
57
Immunotherapies, such as anti-PD-1 and anti-PD-L1, have become standard first line therapies for patients with advanced renal cell carcinoma (kidney cancer). Most patients, however, eventually experience disease progression, ...
Apr 3, 2023
0
54
A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by an oncologist from Dana-Farber Cancer ...
Sep 8, 2022
0
69
